Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients with Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2017-04-28
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 18
- Registration Number
- NCT03132532
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Auto Stem Cell Transplant for Lymphoma Patients
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 150
- Registration Number
- NCT03125642
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
- Conditions
- Interventions
- Drug: PrednisoneDrug: VincristineDrug: DaunorubicinDrug: PegaspargaseDrug: Erwinase®Drug: CyclophosphamideDrug: CytarabineDrug: MercaptopurineDrug: DasatinibDrug: MethotrexateDrug: BlinatumomabDrug: DexamethasoneDrug: RuxolitinibDrug: ThioguanineDrug: BortezomibDrug: Asparaginase Erwinia chrysanthemi (recombinant)-rywnDrug: Calaspargase PegolDrug: DoxorubicinDrug: EtoposideDrug: NelarabineDrug: ClofarabineDrug: VorinostatDrug: Idarubicin
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 790
- Registration Number
- NCT03117751
- Locations
- 🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States
🇺🇸St. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital, Charlotte, North Carolina, United States
🇦🇺The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia
Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT03118466
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts general Hospital, Boston, Massachusetts, United States
Prospective Cohort for Adult Hemophagocytosis
- First Posted Date
- 2017-04-17
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 81
- Registration Number
- NCT03117010
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
- Conditions
- Interventions
- First Posted Date
- 2017-04-17
- Last Posted Date
- 2020-09-16
- Target Recruit Count
- 2
- Registration Number
- NCT03116971
- Locations
- 🇪🇸
Research site 4, Madrid, Spain
🇧🇬Reasearch site 5, Sofia, Bulgaria
🇧🇬Research site 6, Sofia, Bulgaria
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
- Conditions
- Ann Arbor Stage III Noncutaneous Anaplastic Large Cell LymphomaMature T-Cell and NK-Cell Non-Hodgkin LymphomaAngioimmunoblastic T-Cell LymphomaAnn Arbor Stage II Noncutaneous Anaplastic Large Cell LymphomaAnn Arbor Stage IV Noncutaneous Anaplastic Large Cell LymphomaHepatosplenic T-Cell LymphomaEnteropathy-Associated T-Cell LymphomaAdult T-Cell Leukemia/LymphomaAnaplastic Large Cell Lymphoma, ALK-NegativeAnaplastic Large Cell Lymphoma, ALK-Positive
- Interventions
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 48
- Registration Number
- NCT03113500
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
- Conditions
- Lymphocyte-Rich Classical Hodgkin LymphomaRecurrent Lymphocyte-Depleted Classical Hodgkin LymphomaRecurrent Mixed Cellularity Classical Hodgkin LymphomaRecurrent Nodular Sclerosis Classical Hodgkin LymphomaRefractory Lymphocyte-Depleted Classical Hodgkin LymphomaRefractory Mixed Cellularity Classical Hodgkin LymphomaRefractory Nodular Sclerosis Classical Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 43
- Registration Number
- NCT03077828
- Locations
- 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Augusta University Medical Center, Augusta, Georgia, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas
- First Posted Date
- 2017-03-07
- Last Posted Date
- 2018-06-11
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 50
- Registration Number
- NCT03071822
- Locations
- 🇭🇰
The University of Hong Kong, Hong Kong, Hong Kong
Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
- First Posted Date
- 2017-03-07
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 14
- Registration Number
- NCT03072771
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.